Expert Review of Vaccines

Papers
(The H4-Index of Expert Review of Vaccines is 26. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Indirect protection from rotavirus vaccines: a systematic review70
Cost-effectiveness analysis of the use of PNEU-C-21 in adults aged ≥50 years in Canada68
Knowledge, attitudes, and perceptions towards pneumococcal vaccines among adults in the United States59
Progress and challenges in Nipah vaccine development and licensure for epidemic preparedness and response58
Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic50
Monkeypox pandemic containment: does the ACAM2000 vaccine play a role in the current outbreaks?49
Review of scientific evidence to support recommendations of the full-dose DTaP-IPV vaccination in pre-school age children in Italy49
Vaccines against chronic Trypanosoma cruzi infection: progress, challenges and future directions47
Response to letter to the editor on a systematic review of invasive pneumococcal disease vaccine failures and breakthrough with higher-valency pneumococcal conjugate vaccines in children44
Adjuvanted-RSVPreF3 vaccine uptake and effectiveness in individuals with COPD: a nationwide Danish cohort study44
Economic evaluations of 13-valent pneumococcal conjugate vaccine: a systematic review43
Post-marketing surveillance for the safety of the quadrivalent human papillomavirus vaccine: a retrospective real-world study in China43
The protective effects of two varicella vaccination strategies: A Bayesian modeling study in two megacities in South China37
Waning intra-season vaccine effectiveness against influenza A(H3N2) underlines the need for more durable protection36
Addressing barriers to and strategies for herpes zoster vaccination in immunocompromised patients in Türkiye: an expert consensus36
Personal and contextual determinants of COVID-19 vaccination intention: a vignette study36
Comparative effectiveness of Omicron XBB 1.5-adapted COVID-19 vaccines: a systematic literature review and network meta-analysis35
Epidemiological shifts in coxsackievirus A-induced hand, foot, and mouth disease in China, 2008–202434
The important lessons lurking in the history of meningococcal epidemiology33
Clinical development of variant-adapted BNT162b2 COVID-19 vaccines: the early Omicron era31
Research progress on substitution of in vivo method(s) by in vitro method(s) for human vaccine potency assays30
A review of evidence for pneumococcal vaccination in adults at increased risk of pneumococcal disease: risk group definitions and optimization of vaccination coverage in the United Kingdom28
COVID-19 vaccination hesitancy in pregnant and breastfeeding women and strategies to increase vaccination compliance: a systematic review and meta-analysis28
Microarray patches: scratching the surface of vaccine delivery27
Public health impact and cost-effectiveness of the adjuvanted RSVPreF3 vaccine for respiratory syncytial virus prevention among adults aged 50 years and older in Germany27
Addressing RSV infection in older adults: implications for public health policy26
Batch-to-batch consistency trial of an adenovirus type-5 vector-based COVID-19 vaccine in adults aged 18 years and above26
Off-Label use of vaccines may save lives and money: lessons from the province of Quebec, Canada26
Montanide ISA-51: a promising adjuvant in cancer vaccine immunotherapy26
0.45923113822937